Literature DB >> 6243675

Adrenergic mechanisms for the effects of epinephrine on glucose production and clearance in man.

R A Rizza, P E Cryer, M W Haymond, J E Gerich.   

Abstract

THE PRESENT STUDIES WERE UNDERTAKEN TO ASSESS THE ADRENERGIC MECHANISMS BY WHICH EPINEPHRINE STIMULATES GLUCOSE PRODUCTION AND SUPPRESSES GLUCOSE CLEARANCE IN MAN: epinephrine (50 ng/kg per min) was infused for 180 min alone and during either alpha (phentolamine) or beta (propranolol)-adrenergic blockade in normal subjects under conditions in which plasma insulin, glucagon, and glucose were maintained at comparable levels by infusion of somatostatin (100 mug/h), insulin (0.2 mU/kg per min), and variable amounts of glucose. In additional experiments, to control for the effects of the hyperglycemia caused by epinephrine, variable amounts of glucose without epinephrine were infused along with somatostatin and insulin to produce hyperglycemia comparable with that observed during infusion of epinephrine. This glucose infusion suppressed glucose production from basal rates of 1.8+/-0.1 to 0.0+/-0.1 mg/kg per min (P < 0.01), but did not alter glucose clearance. During infusion of epinephrine, glucose production increased transiently from a basal rate of 1.8+/-0.1 to a maximum of 3.0+/-0.2 mg/kg per min (P < 0.01) at min 30, and returned to near basal rates at min 180 (1.9+/-0.1 mg/kg per min). Glucose clearance decreased from a basal rate of 2.0+/-0.1 to 1.5+/-0.2 ml/kg per min at the end of the epinephrine infusion (P < 0.01). Infusion of phentolamine did not alter these effects of epinephrine on glucose production and clearance. In contrast, infusion of propranolol completely prevented the suppression of glucose clearance by epinephrine, and inhibited the stimulation of glucose production by epinephrine by 80+/-6% (P < 0.001). These results indicate that, under conditions in which plasma glucose, insulin, and glucagon are maintained constant, epinephrine stimulates glucose production and inhibits glucose clearance in man predominantly by beta adrenergic mechanisms.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6243675      PMCID: PMC371410          DOI: 10.1172/JCI109714

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  25 in total

1.  Studies on the role of adenosine 3',5'-monophosphate in the hepatic actions of glucagon and catecholamines.

Authors:  J H Exton; G A Robison; E W Sutherland; C R Park
Journal:  J Biol Chem       Date:  1971-10-25       Impact factor: 5.157

Review 2.  The hormonal control of hepatic gluconeogenesis.

Authors:  J H Exton; L E Mallette; L S Jefferson; E H Wong; N Friedmann; T B Miller; C R Park
Journal:  Recent Prog Horm Res       Date:  1970

3.  Adrenergic receptors for metabolic responses in the liver.

Authors:  K R Hornbrook
Journal:  Fed Proc       Date:  1970 Jul-Aug

4.  Regulation of glucose uptake by muscle. 8. Effects of fatty acids, ketone bodies and pyruvate, and of alloxan-diabetes and starvation, on the uptake and metabolic fate of glucose in rat heart and diaphragm muscles.

Authors:  P J Randle; E A Newsholme; P B Garland
Journal:  Biochem J       Date:  1964-12       Impact factor: 3.857

5.  Regulation of human lipolysis. In vivo observations on the role of adrenergic receptors.

Authors:  T W Burns; J M Mohs; P E Langley; R Yawn; G R Chase
Journal:  J Clin Invest       Date:  1974-01       Impact factor: 14.808

Review 6.  Sympathetic regulation of metabolism.

Authors:  J Himms-Hagen
Journal:  Pharmacol Rev       Date:  1967-09       Impact factor: 25.468

7.  Role of beta-adrenergic receptors in counterregulation to insulin-induced hypoglycemia.

Authors:  E A Abramson; R A Arky
Journal:  Diabetes       Date:  1968-03       Impact factor: 9.461

8.  Coated charcoal immunoassay of insulin.

Authors:  V Herbert; K S Lau; C W Gottlieb; S J Bleicher
Journal:  J Clin Endocrinol Metab       Date:  1965-10       Impact factor: 5.958

9.  Glucose metabolism and plasma insulin level during epinephrine infusion in the dog.

Authors:  N Altszuler; R Steele; I Rathgeb; R C De Bodo
Journal:  Am J Physiol       Date:  1967-03

10.  A receptor mechanism for the inhibition of insulin release by epinephrine in man.

Authors:  D Porte
Journal:  J Clin Invest       Date:  1967-01       Impact factor: 14.808

View more
  67 in total

1.  Epinephrine deficiency results in intact glucose counter-regulation, severe hepatic steatosis and possible defective autophagy in fasting mice.

Authors:  Rana I Sharara-Chami; Yingjiang Zhou; Steven Ebert; Karel Pacak; Umut Ozcan; Joseph A Majzoub
Journal:  Int J Biochem Cell Biol       Date:  2012-03-03       Impact factor: 5.085

2.  Adrenaline increases skeletal muscle glycogenolysis, pyruvate dehydrogenase activation and carbohydrate oxidation during moderate exercise in humans.

Authors:  M J Watt; K F Howlett; M A Febbraio; L L Spriet; M Hargreaves
Journal:  J Physiol       Date:  2001-07-01       Impact factor: 5.182

Review 3.  Effects of drugs on glucose tolerance in non-insulin-dependent diabetics (Part II).

Authors:  S O'Byrne; J Feely
Journal:  Drugs       Date:  1990-08       Impact factor: 9.546

4.  β-AR polymorphisms and glycemic and lipid parameters in hypertensive individuals receiving carvedilol or metoprolol.

Authors:  Orly Vardeny; Gabriel Nicholas; Alina Andrei; Kevin A Buhr; Matt P Hermanson; John J Moran; Michelle A Detry; James H Stein
Journal:  Am J Hypertens       Date:  2012-05-31       Impact factor: 2.689

5.  Enhanced glycemic responsiveness to epinephrine in insulin-dependent diabetes mellitus is the result of the inability to secrete insulin. Augmented insulin secretion normally limits the glycemic, but not the lipolytic or ketogenic, response to epinephrine in humans.

Authors:  M A Berk; W E Clutter; D Skor; S D Shah; R P Gingerich; C A Parvin; P E Cryer
Journal:  J Clin Invest       Date:  1985-06       Impact factor: 14.808

6.  Role of epinephrine-mediated beta-adrenergic mechanisms in hypoglycemic glucose counterregulation and posthypoglycemic hyperglycemia in insulin-dependent diabetes mellitus.

Authors:  D A Popp; S D Shah; P E Cryer
Journal:  J Clin Invest       Date:  1982-02       Impact factor: 14.808

7.  Beta-adrenergic blockade is more effective in suppressing adrenaline-induced glucose production in Type 1 (insulin-dependent) diabetes.

Authors:  H Shamoon; R Sherwin
Journal:  Diabetologia       Date:  1984-03       Impact factor: 10.122

8.  Defective glucose counterregulation after subcutaneous insulin in noninsulin-dependent diabetes mellitus. Paradoxical suppression of glucose utilization and lack of compensatory increase in glucose production, roles of insulin resistance, abnormal neuroendocrine responses, and islet paracrine interactions.

Authors:  G B Bolli; E Tsalikian; M W Haymond; P E Cryer; J E Gerich
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

9.  Evaluation of insulin resistance during inhibition of endogenous insulin and glucagon secretion by somatostatin in non-obese subjects with impaired glucose tolerance.

Authors:  K P Ratzmann; W Besch; S Witt; B Schulz
Journal:  Diabetologia       Date:  1981-09       Impact factor: 10.122

10.  Inhibitory effect of epinephrine on insulin-stimulated glucose uptake by rat skeletal muscle.

Authors:  J L Chiasson; H Shikama; D T Chu; J H Exton
Journal:  J Clin Invest       Date:  1981-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.